HealthDay Reports: Hydroxychloroquine May Worsen Odds for Cancer Patients With COVID-19
Researchers found that cancer patients with COVID-19 who receive both hydroxychloroquine and the antibiotic azithromycin have a higher risk of death than those who aren't given the two drugs.
Hydroxychloroquine May Worsen Odds for Cancer Patients With COVID-19
THURSDAY, May 28, 2020 (HealthDay News) -- As the evidence piles up that a malaria drug touted as a possible coronavirus treatment by President Donald Trump may instead harm patients, a new study shows the same might hold true for cancer patients with COVID-19.
Researchers found that cancer patients with COVID-19 who receive both hydroxychloroquine and the antibiotic azithromycin have a higher risk of death than those who aren't given the two drugs.
Of the 928 patients in the study, 13% died within 30 days of being diagnosed with COVID-19. After adjusting for certain factors, the researchers concluded that patients with progressing cancer were 5.2 times more likely to die within 30 days than those in remission or with no evidence of cancer.